Powerful Experiences Lie at the Intersection of Design and Strategy

Whether you’re an integrator, a designer or simply a label-defying creative, the EXPERIENCE is everything. Host Bryan Meszaros explores the story behind the exhibit to understand how a carefully crafted experience traps into the human experience to connect people to place.

 

On this episode of Experience By Design, Host Bryan Meszaros talked with Matthew McNerney, Creative Director, Experience, Landor & Fitch, an iconic design and strategy agency that delivers extraordinary brand transformation by design. They spoke about his career, career trajectory, and Landor & Fitch.

McNerney recently landed at Landor & Fitch, where he directs brand experiences to transform businesses, foster affinity, and build brand ambassadors. His fluid role spans physical environments, programming, service design, and digital interaction, and he often leads business development efforts from ideation through pitch presentations. He promotes collaboration while cultivating space for team members to influence projects from any direction.

“The reality of experience design is that it touches everything.” – Matthew McNerney

Landor is known for its classic branding, strategic design, and legacy contributions to the graphic design world. Fitch is known for its world-class strategy, experience, retail, and workplace design.

“It is really the two ends of the spectrum of branding, so bringing them together to offer our extraordinary work is incredible,” McNerney said.

He elaborated that they noticed clients were asking for more coherent deliverables. The two practices of design and strategy from Landor & Fitch integrate the two disciplines to create holistic experiences.

“The reality of experience design is that it touches everything,” McNerney said. “Having those two minds is just lovely to really offer incredibly rich solutions for an evolving world that’s only accelerated since the pandemic.”

Listen to Previous Episodes!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More